BIOtechNOW News & Videos - Business Development Sponsor Logo

Finance Policy


Rachel King, CEO, GlycoMimetics (BIO Chair) with Kate Neville (Women in Bio)
David Kappos, Former Director, USPTO, Current Partner Cravath, Swaine and Moore, LLP
Show Me the Money: Reimbursement in an ACA World
Jennifer Griffiths, Chief Mission Officer of the Arthritis Foundation.
Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff Featuring John Podesta
BioCentury This Week with janet Woodcock, Kiran Mazumdar-Shaw, Margaret Hamburg, and Francis Collins
Seth Ginsberg, President, Global Healthy Living Foundation
Governor Jay Nixon, Missouri
David Kappos, Former Director, USPTO, Current Partner Cravath, Swaine and Moore, LLP
Neal Carter, President, Okanagan Speciality Fruit
Dr. Stephen Spielberg, former Deputy Commissioner of the FDA
Fred Horne, Minister of Health and Wellness - Alberta
Governor Steve Beshear, Kentucky
BioCentury This Week

Articles from BioTechNow

Finding Biotech in the Silicon Prairie

Posted: 4/23/23013 By: Jeffrey Aronin

The Silicon Prairie is about more than technology companies and Internet start-ups. In fact, the biotech industry in Illinois employs nearly 80,000 people, according to a recent analysis by Battelle, and their salaries are double the salary of the average private sector worker in the state. 

Read More >

Debt, Taxes and Politics: Is There a Way Out?

Publish Date: 4/25/2013, Created By: BIOtechNOW Editor

BIO President and CEO Jim Greenwood kicked off a keynote discussion with Sen. Alan Simpson and Erskine Bowles at the BIO International Convention, saying public policy can make or break the biotech industry’s best efforts to deliver innovations that make our world a better place, and then asked the esteemed duo if our government can make the tough choices needed to keep our economy strong. “You can’t tax your way out of this hole, you can’t cut spending your ...

Read More >

The Justness of Gene Patents

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor

Most of the biotechnology world awaits the U.S. Supreme Court’s answer to the Question Presented, “Are human genes patentable,” in the Association of Molecular Pathologists et al. v. Myriad Genetics case. Claims to “human genes” have a canonical form that has been developed over the thirty years during which “genes” (human or otherwise) have been patented under U.S. law: An isolated nucleic acid having a nucleotide sequence that encodes a protein having an amino acid ...

Read More >

Governors Share Best Practices on Bringing Biotech Jobs to their States

Publish Date: 4/24/2013, Created By: BIOtechNOW Editor

With the state competition for biotech jobs in full force at the BIO International Convention, BIO released its Bioscience Economic Development report yesterday to a standing room only crowd that came to hear Texas Gov. Rick Perry, Pennsylvania Gov. Tom Corbett, Missouri Gov. Jay Nixon and Director of Illinois Department of Commerce and Economic Opportunity Jack Lavin share their insights on attracting and growing the biotech industry within their states. Common themes quickly emerged around ...

Read More >

Patent Utility Requirements for Biopharmaceutical Inventions: How Much is Enough?

Publish Date: 4/19/2013, Created By: BIOtechNOW Editor

A debate between the innovative and generic perspectives on pharmaceutical patent law in Canada, moderated by David Kappos, will be held in Chicago on Monday April 22nd from 2:30-3:30pm in room S404A at this year’s BIO International Convention. Former Undersecretary of Commerce for Intellectual Property and USPTO Director David J. Kappos will moderate a panel of legal experts who will discuss recent developments in the area of patent utility and its implications for biopharmaceutical innovation.  ...

Read More >

Patent and Tech Transfer Sessions at 2013 BIO International Convention

Publish Date: 4/8/2013, Created By: Roy Zwahlen

Patent and Technology Transfer sessions feature prominently at the 2013 BIO International Convention in Chicago from April 22-25, 2013. Topics cover developing patent and tech transfer issues in the U.S. and internationally. Many of the sessions provide Continuing Legal Education (CLE) and Registered Technology Transfer Professional (RTTP) credits. The Biotech Patenting and Technology Transfer Track sessions are below: Behind the Tech Transfer Headlines: What are You Missing? Headline-making news reports of multiyear, multimillion dollar strategic ...

Read More >

GEN’s “Top 10” Session Picks for the 2013 BIO International Convention

Publish Date: 3/19/2013, Created By: BIOtechNOW Editor

As the industry moves forward in 2013, it again faces one of its regular bugaboos—uncertainty. “Where are we headed?” has been a standard phrase among bioindustry observers since the early 1980s. As it turns out, the biopharmaceutical business must once again deal with a number of important issues this year. For example, G. Steven Burrill, CEO of Burrill & Co., points out that the cuts mandated by the U.S. Congress’ sequestration fiscal policy may slow ...

Read More >

Simpson Bowles Keynote to Address Debt, Taxes, Government Services and Politics

Publish Date: 2/4/2013, Created By: Jim Greenwood

I was recently asked what the single biggest threat to the biotechnology industry is today.  My answer was immediate – the biggest threat to biotech innovation is the unsustainable mismatch of spending and revenue in the U.S. federal budget. The enormous national debt and the huge annual budget deficits that feed it endanger America’s entire economic future – but the nation’s dire fiscal situation is particularly threatening to our industry. Part of the reason for ...

Read More >

2013 BIO International Convention Program Highlights

Publish Date: 1/30/2013, Created By: BIOtechNOW Editor

I’m thrilled to be attending the upcoming 2013 BIO International Convention that is coming to Chicago April 22-25. The educational sessions, networking, business forum, and exhibits are coming together to form the strongest Convention to date. Of course, I may be biased being a Chicago native but I can’t think of a better venue and backdrop for the rapidly evolving biotechnology industry. The City of Chicago is known for its architects and novel designs, a ...

Read More >